The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
Systematic review and meta-analysis reveals increased cardiovascular risk with elevated non-HDL apolipoprotein CIII in patient cohorts, indicating its potential value as an atherogenic biomarker.
Key Points
- To review the association between blood apolipoprotein CIII (apoC-III) concentrations and cardiovascular events, including the dose-response relationship across different lipoprotein fractions.
- Systematic review of MEDLINE, EMBASE, BIOSIS, CINAHL, Clinicaltrials.gov, reference lists, and grey literature without language restrictions.
- Synthesized data from 12 studies (5 retrospective and 7 prospective) encompassing 3,163 total cases of cardiovascular events.
- Patients with cardiovascular disease had significantly higher apoC-III levels in the non-HDL fraction (VLDL and LDL) compared with controls, a trend toward higher total plasma apoC-III, and no difference in HDL apoC-III.
- Each 5-mg/dL increase in apoC-III yielded pooled risk estimates of 2.48 (95% CI, 1.48–4.32) for non-HDL apoC-III, 1.33 (95% CI, 1.07–1.66) for total apoC-III, and 1.09 (95% CI, 0.65–1.82) for HDL apoC-III.
Cite This Study
Ballmoos et al. (2015) studied this question.